Cargando…

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases

Background: In the last years, inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection management has completely changed. However, the role of direct-acting antivirals (DAAs) and the correct timing of antiviral drugs administration in IBD patients needing biologics has not been evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imperatore, Nicola, Castiglione, Fabiana, Rispo, Antonio, Sessa, Anna, Caporaso, Nicola, Morisco, Filomena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702483/ https://www.ncbi.nlm.nih.gov/pubmed/29209223 http://dx.doi.org/10.3389/fphar.2017.00867

Ejemplares similares

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease
por: Tortora, Raffaella, et al.
Publicado: (2018)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
por: Rispo, Antonio, et al.
Publicado: (2016)

Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life
por: Sabbatini, Massimo, et al.
Publicado: (2018)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
por: Rinaldi, Luca, et al.
Publicado: (2019)

Noninvasive monitoring of inflammatory bowel disease in the post COVID-19 era
por: Nardone, Olga Maria, et al.
Publicado: (2020)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak
por: Nardone, Olga Maria, et al.
Publicado: (2020)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
por: Guarino, Maria, et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Ultrasonography-Based Management of Sclerosing Mesenteritis: From Diagnosis to Follow-Up
por: de Sire, Roberto, et al.
Publicado: (2021)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
por: Cossiga, Valentina, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
por: Kondili, Loreta A., et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Association between Health-Related Quality of Life and Nutritional Status in Adult Patients with Crohn’s Disease
por: Cioffi, Iolanda, et al.
Publicado: (2020)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Cyclic Neutropenia Mimicking Crohn’s Disease: Two Case Reports and a Narrative Review
por: Guarino, Alessia Dalila, et al.
Publicado: (2023)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
por: Nabulsi, Nadia A., et al.
Publicado: (2020)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

2223. Effect of Direct-Acting Antivirals in Hemodialysis Patients with HCV: Real-Life Data
por: Aydin, Nurten Nur, et al.
Publicado: (2018)

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients
por: Pietrosi, Giada, et al.
Publicado: (2020)

Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals
por: Mohamed, Salem Y., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f5tf9hbi02bohr9ik4o5pqhi20